- Home
- QURE vs CMPS Comparison
QURE vs CMPS Comparison
Compare QURE & CMPS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | QURE | CMPS |
|---|---|---|
| Founded | 1998 | 2020 |
| Country | Netherlands | United Kingdom |
| Employees | 248 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.2B |
| IPO Year | 2013 | 2020 |
Fundamental Metrics
Financial Performance| Metric | QURE | CMPS |
|---|---|---|
| Price | $27.85 | $12.89 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 14 | 8 |
| Target Price | ★ $45.00 | $25.38 |
| AVG Volume (30 Days) | 1.9M | ★ 3.9M |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 29.67 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $13,107,000.00 | N/A |
| Revenue This Year | $126.12 | N/A |
| Revenue Next Year | $200.43 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $8.73 | $2.25 |
| 52 Week High | $71.50 | $13.10 |
Technical Indicators
Market Signals| Indicator | QURE | CMPS |
|---|---|---|
| Relative Strength Index (RSI) | 68.49 | 72.54 |
| Support Level | $20.20 | $4.66 |
| Resistance Level | $29.03 | N/A |
| Average True Range (ATR) | 1.74 | 0.84 |
| MACD | -0.17 | 0.13 |
| Stochastic Oscillator | 75.56 | 97.81 |
Price Performance
Historical ComparisonAbout QURE uniQure N.V.
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases. Its program and pipeline involves: Huntington's Disease, Temporal Lobe Epilepsy (TLE), Fabry Disease, ALS (SOD1), Hemophilia B, Clinical Trials, and Research Programs.
About CMPS COMPASS Pathways Plc American Depository Shares
Compass Pathways PLC is a biotechnology company focused on developing therapies for mental health conditions. Its research centers on a proprietary synthetic psilocybin formulation, COMP360, which is administered alongside psychological support. The company is conducting clinical trials to evaluate the safety and efficacy of this treatment in patients with treatment-resistant depression and other mental health disorders. The company operates in one operating segment.